Serine Protease HTRA1 Membranous Nephropathy With Polytypic IgG Concurrent With Plasma Cell Dyscrasia

By afschroeder • June 16, 2026

Zuckerman JE, Larson S, Abdelnour L. Serine Protease HTRA1 Membranous Nephropathy With Polytypic IgG Concurrent With Plasma Cell Dyscrasia. Kidney Med. 2026 May 12;8(7):101402. doi: 10.1016/j.xkme.2026.101402. PMID: 42290670; PMCID: PMC13254867.

Tags: Hematology/Oncology, HTRA1, IgA-lambda multiple myeloma, membranous nephropathy, Multiple myeloma, Nephrology, nephropathology, paraneoplastic membranous nephropathy, plasma cell dyscrasia HTRA1-associated membranous nephropathy, plasma cell neoplasm, polytypic IgG, progressive proteinuria, Publications, renal pathology

daNIS-2: a phase III, randomized, double-blind study of the anti-TGF-β monoclonal antibody NIS793 or placebo in combination with nab-paclitaxel/gemcitabine as first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma

Paulson S, Ikeda M, Shen L, Stein A, Macarulla T, Milella M, Golan T, Wainberg Z, Taieb J, Wang L, Polydoros F, Abecunas C, López[...]

Anti-trophoblast Cell-Surface Antigen 2 (TROP2)-Based Therapy for Concurrent Breast and Thyroid Malignancies

Berkowitz MJ, Arzoo KK. Anti-trophoblast Cell-Surface Antigen 2 (TROP2)-Based Therapy for Concurrent Breast and Thyroid Malignancies. Cureus. 2026 Oct 6;18(10):e117545. doi: 10.7759/cureus.117545. PMID: 42992212; PMCID:[...]

PADL1NK-005 study design: a phase III trial of fetrastobart vedotin (Fetra-V) vs docetaxel in patients with previously treated tumor PD-L1-positive NSCLC

Altan M, Navani V, Kim HR, Sun L, Paz-Ares L, Chmielewska I, Lin CC, Cuppens K, Mountzios I, Peled N, Cappuzzo F, Wang B, Zhou[...]